JY
HCWB icon

Jeff Yass’s HCW Biologics HCWB Stock Holding History

Jeff Yass’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,345
Closed -$19.5K – 13537
2025
Q4 		$19.5K Buy
+3,345
New +$56.8K ﹤0.01% 11970

Other funds holding HCWB

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jeff Yass's HCWB Position: Q1 2026 in Review

Jeff Yass sold out of HCW Biologics (HCWB) in Q1 2026, closing a stake of 3,345 shares — an estimated $19.5K sold.

Jeff Yass first reported a position in HCWB in Q4 2025 and held it in 1 quarter. The position peaked at $19.5K in Q4 2025. 13 funds tracked by Wall St. Rank hold HCWB as of Q1 2026.

  • Jeff Yass reported no remaining HCW Biologics position as of Q1 2026 after selling out during the quarter.
  • Jeff Yass sold 3,345 HCW Biologics shares in Q1 2026, an estimated $19.5K.
  • Jeff Yass first reported a position in HCW Biologics in Q4 2025 and held it in 1 quarter.
  • Jeff Yass's HCW Biologics position peaked at $19.5K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held HCW Biologics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.